Monoclonal gammopathy defines distinct clinical subsets in chronic lymphocytic leukemia across therapeutic eras.

Blood Adv · 2025 · PMC12744275 · PMID 40902084

Europe PMC DOI

hedged sentence

0.0640

closest p · 1.3× alpha

0.0640

boldest claim

The sentences

did not reach statistical significanceP = .064so close (0.05 < p ≤ 0.1)

In patients receiving targeted therapy as first-line treatment, those with IgM-MG had a trend toward inferior PFS compared with IgM-MG–negative counterparts, though this difference approached but did not reach statistical significance (median PFS: 39 vs 82 months; P = .064).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.